Prolonged-release nicotinic acid in patients with atherosclerotic disease in The Netherlands

European Surgical Research

Volumn 41, Issue 4, 2008, Pages 313-318

  Poldermans, D ^a   Dunkelgrun, M ^a   Schouten, O ^a   Hostalek, U ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MERCK KGAA   (Germany)

Author keywords

Atherosclerotic disease; Dyslipidaemia; High density lipoprotein cholesterol; Niacin; Nicotinic acid, tolerability

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ARTICLE; ATHEROSCLEROSIS; BURNING SENSATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FLUSHING; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NETHERLANDS; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SIDE EFFECT; SLEEP DISORDER; UPPER ABDOMINAL PAIN;

ADULT; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DELAYED-ACTION PREPARATIONS; FEMALE; FLUSHING; HUMANS; MALE; MIDDLE AGED; NIACIN; PROSPECTIVE STUDIES;

EID: 51749118029     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000155896     Document Type: Article

References (39)

1. Criqui MH, Langer RD, Fronek A, et al: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386.
2. Valentine RJ, Grayburn PA, Eichhorn EJ, Myers SI, Clagett GP: Coronary artery disease is highly prevalent among patients with premature peripheral vascular disease. J Vasc Surg 1994;19:668-674.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, et al: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-1610.
4. Rydén L, Standl E, Bartnik M, et al: Guidelines on diabetes, pre-diabetes and cardiovascular diseases: full text. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J Suppl 2007;9:C3-C74.
5. Baigent C, Keech A, Kearney PM, et al: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
6. Kastelein JJP: The realities of dyslipidaemia: what do the studies tell us? Eur Heart J Suppl 2005;7:F27-F33.
7. Colhoun HM, Betteridge DJ, Durrington PN, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre random ised placebo-controlled trial. Lancet 2004;364:685-696.
8. The TIMI Study Group: Results of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) trial. www.timi.org.
9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714.
10. Wilson PW, Abbott RD, Castelli WP: High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-741.
11. Goldbourt U, Yaari S, Medalie JH: Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8,000 men. Arterioscler Thromb Vasc Biol 1997;17:107-113.
12. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-2838.
13. Assmann G, Schulte H, von Eckardstein A, Huang Y: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(suppl):S11-S20.
14. Gordon DJ, Probstfield JL, Garrison RJ: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
15. Turner RC, Millns H, Neil HA, et al: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-828.
16. Aboyans V, Criqui MH, Denenberg JO, et al: Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006;113:2623-2629.
17. Garg R, Elam MB, Crouse JR, et al: Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am Heart J 2000;140:792-803.
18. Brown BG: Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. Eur Heart J Suppl 2005;7:F34-F40.
19. Brown BG: Niaspan® in the management of dyslipidaemia: the evidence. Eur Heart J Suppl 2006;8:F60-F67.
20. McGovern M: Niaspan®: creating a new concept for raising HDL-cholesterol. Eur Heart J Suppl 2005;7:F41-F47.
21. Knopp RH, Alagona P, Davidson M, et al: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-1104.
22. Taylor AJ, Sullenberger LE, Lee H, et al: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2:a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-3517.
23. Taylor AJ, Lee HJ, Sullenberger LE: The effect of 24 months of combination statin and extended-release niacin on carotid intimamedia thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-2250.
24. Birjmohun RS, Kastelein JJP, Poldermans D, Stroes ESG, Hostalek U, Assmann G: Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. Curr Med Res Opin 2007;23:1707-1713.
25. Niaspan® prescribing information. Darmstadt, Merck Serono, http://www.merck-pharmaceuticals.co.uk/default.htm.
26. Assmann G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002;105:310-315 (erratum in Circulation 2002;105:900).
27. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, et al: ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease); endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, National Heart, Lung and Blood Institute, Society for Vascular Nursing, Transatlantic Inter-Society Consensus, and Vascular Disease Foundation. Circulation 2006;113:e463-e654.
28. Hirsch AT, Criqui MH, Treat-Jacobson D, et al: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-1324.
29. Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418.
30. Garg R, Elam MB, Crouse JR, et al: Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am Heart J 2000;140:792-803.
31. Empana JP, Ducimetière P, Arveiler D, et al: Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003;24:1903-1911.
32. Bruckert E, Baccara-Dinet M, McCoy F, et al: High prevalence of low HDL-cholesterol in a pan-European survey of 8,545 dyslipidaemic patients. Curr Med Res Opin 2005;21:1927-1934.
33. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C: Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-1268.
34. Gotto AM Jr, Brinton EA: Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004;43:717-724.
35. Nissen SE, Tardif JC, Nicholls SJ, et al: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-1316.
36. Kastelein JJ, van Leuven SI, Burgess L, et al: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-1630.
37. Yvan-Charvet L, Matsuura F, Wang N, et al: Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007;27:1132-1138.
38. Tall AR, Yvan-Charvet L, Wang N: The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007;27:257-260.
39. Shepherd J: Raising HDL-cholesterol and lowering CHD risk: does intervention work? Eur Heart J Suppl 2005;7:F15-F22.